Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accumulated Depreciation (2021 - 2025)

Lyra Therapeutics has reported Accumulated Depreciation over the past 5 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $4.5 million for Q4 2025, up 10.17% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (up 10.17% YoY), and the annual figure for FY2025 was $4.5 million, up 10.17%.
  • Accumulated Depreciation for Q4 2025 was $4.5 million at Lyra Therapeutics, up from $4.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for LYRA hit a ceiling of $4.7 million in Q3 2022 and a floor of $1.9 million in Q4 2023.
  • Median Accumulated Depreciation over the past 5 years was $4.1 million (2022), compared with a mean of $3.7 million.
  • Biggest five-year swings in Accumulated Depreciation: tumbled 53.98% in 2023 and later skyrocketed 114.94% in 2024.
  • Lyra Therapeutics' Accumulated Depreciation stood at $3.9 million in 2021, then increased by 7.61% to $4.2 million in 2022, then tumbled by 53.98% to $1.9 million in 2023, then skyrocketed by 114.94% to $4.1 million in 2024, then increased by 10.17% to $4.5 million in 2025.
  • The last three reported values for Accumulated Depreciation were $4.5 million (Q4 2025), $4.4 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.